The broad, long-term goal of our program is to advance the knowledge of virus-host cell interactions by characterizing cellular cofactors essential for hepatitis C virus (HCV) infection. HCV infects 170 million people worldwide and is major cause of hepatocellular carcinoma. Understanding how this virus interacts with the host is of critical importance to the development of diagnostics, antiviral drugs, and a prophylactic vaccine. Our previous studies demonstrated that HCV infection of cultured hepatoma cells is critically dependent on a cellular protein, cyclophilin A (CyPA), and that ablating the function of this protein can not only prevent new infections but also suppress an existing infection. In addition, CyPA is a principal mediator of HCV resistance to cyclosporine A (CsA) and its derivatives, which inhibit HCV replication with an undefined mechanism and are currently being evaluated in clinical trials as candidate anti- HCV drugs. The experiments proposed here will investigate the molecular mechanisms that determine the essential cofactor function of CyPA, the action of CsA, and the related CsA resistance. The following experiments will be performed: (1) CsA and small interfering RNA directed at CyPA mRNA will be used to identify the specific function of HCV replicase that requires CyPA as a cofactor. A detailed understanding of why and where the virus needs this cellular chaperone to survive will offer new perspectives on the replication strategy of HCV. (2) Biochemical assay and mutagenesis will be used to characterize the critical interaction between CyPA and the viral replicase, which represents a novel structural interface of virus-host cell interaction that maybe disrupted for therapeutic purposes. (3) Macromolecular interaction and reverse genetics will be employed to dissect the mode of action for CsA and molecular basis of CsA resistance with the ultimate goal of predicting and circumventing that resistance. The results of the proposed studies will not only provide significant insights into how highly successful parasites such as human viruses hijack host cell machineries to replicate efficiently but also reveal new therapeutic targets for antiviral intervention.
Hepatitis C virus (HCV) infects 3% of the world's population and cause fibrosis, liver cirrhosis and hepatocellular carcinoma (HCC). No prophylactic vaccine exists, and both the current treatment and the drugs in the development pipeline face serious drug- resistance issues. The proposed research will illustrate the molecular basis of drug resistance for a new drug candidate and may also identify a novel aspect of virus-host cell interaction than can serve as target for a new class of drugs.
|Qian, Xuyu; Nguyen, Ha Nam; Song, Mingxi M et al. (2016) Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV Exposure. Cell 165:1238-54|
|Wu, Xianfang; Lee, Emily M; Hammack, Christy et al. (2014) Cell death-inducing DFFA-like effector b is required for hepatitis C virus entry into hepatocytes. J Virol 88:8433-44|
|Frausto, Stephen D; Lee, Emily; Tang, Hengli (2013) Cyclophilins as modulators of viral replication. Viruses 5:1684-701|
|Nag, Anita; Robotham, Jason M; Tang, Hengli (2012) Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J Virol 86:12616-24|
|GrisÃ©, Henry; Frausto, Stephen; Logan, Timothy et al. (2012) A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility. J Virol 86:4811-22|
|Wu, Xianfang; Robotham, Jason M; Lee, Emily et al. (2012) Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog 8:e1002617|
|Jiang, Jieyun; Cun, Wei; Wu, Xianfang et al. (2012) Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 86:7256-67|
|Yang, Feng; Robotham, Jason M; Grise, Henry et al. (2010) A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach. PLoS Pathog 6:e1001118|
|Tang, Hengli (2010) Cyclophilin inhibitors as a novel HCV therapy. Viruses 2:1621-34|